Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System

NCT06485232 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT06485232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06485232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 28, 2025
Completion date
December 31, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyradiculoneuropathy, multiple sclerosis, myasthenia gravis, generalized, neuromyelitis optica spectrum disorders